TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07124221: A Randomized, Double-blind, Double-dummy, Positive Controlled, Multicenter Clinical Study to Evaluate the Efficacy and Safety of Cabergoline Tablets Compared With Bromocriptine Mesylate Tablets in Female Patients With Hy

Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd. · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 382 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$15,086,080

Rescue Site Savings

+$9,947,384

Unlock Full NCT07124221 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07124221 Rescue Dossier →